

cyclomedica technegas cyclopet ultralute

29 May 2018

Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

Results of Annual General Meeting on 29 May 2018

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out below.

Item 1 – Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
32,043,700	10,992	108,990	21,705

This resolution was passed on a show of hands.

Item 2 – Re-Election of Mr Vanda Gould

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
27,227,779	4,935,903	-	21,705

This resolution was passed on a show of hands.



Item 3 – Share Buy-back

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
32,154,829	8,853	-	21,705

This resolution was passed on a show of hands.

Item 4 – Loan Share Plan

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
32,043,700	14,662	105,320	21,705

This resolution was passed on a show of hands.

Janes & MCBreyer

James McBrayer Managing Director and Company Secretary

For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411 M:+61 (0) 0418 967 073